Analyst firms · H.C. Wainwright · NTLA
H.C. Wainwright NTLA price target and rating history
Intellia Therapeutics Inc. (NTLA) · Health Care
H.C. Wainwright rates Intellia Therapeutics Inc. (NTLA) Buy with a $30 price target, as of its latest action on Mar 5, 2025. It has published 3 rating actions on NTLA since June 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $30
- Median target, all firms
- Too few
- Actions on NTLA
- 3
H.C. Wainwright price target on NTLA
Every H.C. Wainwright rating on NTLA
- Mar 5, 2025
- Nov 5, 2021
- Jun 28, 2021
How other firms rate NTLA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $8 | Oct 6, 2026 |
| Wolfe Research | Underperform | $9 | Jul 16, 2026 |
| William Blair | Outperform | Mar 2, 2026 |
Questions about H.C. Wainwright and NTLA
- What is H.C. Wainwright's price target for NTLA?
- H.C. Wainwright's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $30, from its action on Mar 5, 2025.
- What is H.C. Wainwright's rating on NTLA?
- H.C. Wainwright rates NTLA Buy, a bullish rating, as of Mar 5, 2025.
- When did H.C. Wainwright last change its view on NTLA?
- On Mar 5, 2025, H.C. Wainwright starts coverage at Buy, price target $30.
More NTLA rating histories
All H.C. Wainwright ratingsNTLA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.